Business Wire

BIONET-EUROPE

Share
BioNet’s Recombinant Pertussis Vaccine Submitted to European Medicines Agency (EMA)

BioNet Europe, the French subsidiary of BioNet, a vaccine manufacturer specializing in the development of genetically engineered vaccines, has announced the submission of a centralized Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its monovalent Recombinant Pertussis Vaccine (RPV).

BioNet’s stand-alone vaccine targets whooping cough, a highly contagious respiratory disease on the steep rise across Europe. This non-combined vaccine is tailored to the persons who require pertussis-only booster vaccination and are up-to-date with their diphtheria and tetanus immunizations.

Dr Giuseppe Del Giudice, Director Translational Research at BioNet, stated, “BioNet’s recombinant vaccine is designed to provide more effective and longer-lasting immune protection against pertussis than traditional acellular pertussis vaccines. It contains a Pertussis Toxin (PT), the main component responsible for severe pertussis disease, which is inactivated by recombinant technologies rather than chemicals.”

These recombinant technologies allow for the preservation of the native structure of the PT, fundamental for the induction of higher immune protection. Currently, no other monovalent or recombinant pertussis vaccines are available in Europe, making BioNet’s RPV a best-in-class vaccine driving significant advancement in public health with the potential to improve acceptance for pertussis immunization.

Phillippe Guillot-Chene, CEO of BioNet Europe, added, “We believe that BioNet’s RPV represents a transformative vaccine for preventing pertussis disease. After receiving the positive feedback from EMA Scientific Advice, we are honored to have our MAA submission validated by the EMA as well.”

The safety, immunogenicity and antibody persistence induced after one single booster dose of BioNet’s RPV were demonstrated in numerous randomized clinical trials, notably amongst adults in Australia, adolescents in Switzerland, as well as vulnerable populations such as pregnant women and elderly in Thailand.

The vaccine is licensed in Asia (under the Pertagen® trademark) and is included in the pertussis maternal immunization program for pregnant women in Thailand. The MAA of Pertagen® has also been submitted to the Australian Therapeutic Goods Administration.

About BioNet

BioNet is a vaccine manufacturer specializing in the development of recombinant and mRNA vaccines against respiratory diseases and other global public health threats. BioNet has a strong track record with development and biomanufacturing, having advanced over three proprietary recombinant pertussis vaccines from early R&D to licensure. It currently markets multiple vaccines through its established commercial network. BioNet has been rapidly expanding its operations across Asia, Europe and North America.

Forward-Looking Statements

This press release contains forward-looking statements relating to BioNet’s business, including regulatory submissions. These statements are based on current expectations as of the date of this press release and involve known and unknown risks and uncertainties that may cause actual results to differ materially. BioNet disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether due to new information, future events, or otherwise.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240730521754/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

TriLink BioTechnologies® and Aldevron Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology4.2.2025 22:01:00 CET | Press release

Enabling the future development of critical therapeutics, Aldevron customers now have access to TriLink’s CleanCap mRNA capping technology for non-commercial use TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Aldevron, a leading, global Contract Development and Manufacturing Organization (CDMO) providing high-quality plasmid DNA, RNA, and proteins for research, therapeutics, and diagnostics. With this agreement with Aldevron, TriLink strengthens its objective to provide greater access to CleanCap® mRNA capping technologies to those developing critical mRNA-based therapeutics and vaccines. According to the terms of the agreement, TriLink will supply its patented CleanCap® M6, CleanCap® AG 3’OMe, CleanCap® AG, and CleanCap® AU cap analogs for use in Aldevron’s mRNA development and manufacturing services, from pre-clinical through Phas

Telcoin Granted Approval to Open Nebraska’s First Digital Asset Bank4.2.2025 20:32:00 CET | Press release

Regulators give green light for first regulated bank explicitly authorized to connect US consumers to decentralized finance, ushering in a new era of blockchain-integrated banking. Telcoin, a pioneer in blockchain-based financial services, announced that its application to become Nebraska’s first Digital Asset Depository Institution has been conditionally approved by the state’s Department of Banking and Finance. This approval brings Telcoin Bank, a Digital Asset Bank, another step closer to creating the first real bridge between traditional finance and cryptocurrencies. Telcoin Bank is now poised to become the first regulated crypto bank in the United States. Its upcoming launch is expected to disrupt the US$200 billion stablecoin market and transform the financial landscape by offering fully regulated, bank-issued “Digital Cash” stablecoins, as well as an innovative suite of blockchain banking products and services. This development promises to accelerate the adoption of crypto in ma

HTEC and AI Inference Hardware Startup, d-Matrix, Announce Strategic Partnership4.2.2025 19:23:00 CET | Press release

HTEC, a global consulting, software, and digital product development company, is proud to announce a strategic partnership with d-Matrix, the creator of Corsair™, the world’s most efficient AI computing platform for inference in datacenters. HTEC Advisory Board member Sasha Ostojic, who also sits on d-Matrix's Board of Directors, was instrumental in connecting the companies and expediting the collaboration. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250204571709/en/ HTEC announces partnership with d-Matrix, the creator of Corsair™, the world’s most efficient AI computing platform for inference in datacenters (Graphic: Business Wire) During their work together, HTEC will leverage its extensive expertise in AI and embedded software development to support d-Matrix in the development of its software solution. Additionally,HTEC will use an active management approach to proactively identify and address issues and robust report

Monroe Capital Hires Galen Fu as Director, Business Development and Opens Australia Office4.2.2025 17:00:00 CET | Press release

Monroe Capital LLC (“Monroe”) today announced it has expanded its platform to Australia with the appointment of Galen Fu as Director, Business Development. Fu will be based in the firm’s Sydney, Australia office and will be responsible for client servicing and capital raising across Australia. Fu has more than 14 years of experience in capital raising, portfolio management and banking in the Asia-Pacific region. Prior to Monroe, he was a Director in the Capital Markets team at Hines Investment Management where he was responsible for business development and investor relations across Australia. He previously held roles at MaxCap Investment Management (a subsidiary of Apollo Global Management), Westpac Bank and ANZ Bank. Fu earned his B.A. in Commerce and Economics from the University of New South Wales. “We have several long-standing limited partners in Australia and we look forward to our continued strategic growth and expansion in Australia,” said Zia Uddin, President of Monroe Capita

NTT DATA, Inc. Appoints Sudhir Chaturvedi as Global Chief Growth Officer and North America CEO4.2.2025 17:00:00 CET | Press release

NTT DATA, a global digital business and IT services leader, today announced that Sudhir Chaturvedi will join NTT DATA, Inc. as its Global Chief Growth Officer and North America Chief Executive Officer. In the newly created Global Chief Growth Officer role, Chaturvedi will lead the acceleration of consistent growth strategies globally, with special focus on global industries, strategic accounts, and joint go-to-market execution with key strategic partners. In his North America CEO role, Chaturvedi will lead NTT DATA Inc.’s growth and business in this strategic region, while leveraging synergies with his Global Chief Growth Officer remit. Chaturvedi succeeds Eric Clark who is leaving the company for a leadership role outside of NTT DATA. Chaturvedi will report to Abhijit Dubey, President and Global CEO of NTT DATA, Inc., and plans to be based in Plano, TX. “Sudhir has a unique blend of expertise across Consulting, IT Services and Software, alongside industry, digital transformation and s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye